Seattle Genetics (SGEN) PT Raised to $138 at SVB Leerink, Following Updated Results from Phase 1b/2 Trial of PADCEV Bladder Cancer Drug
Tweet Send to a Friend
SVB Leerink analyst Andrew S ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
